Table 1.
Baseline Characteristics for the Intent-to-Treat Population by Randomization Group (n [%] or mean ± SD)
| Zoledronic acid (n = 3875) | Placebo (n = 3861) | |
|---|---|---|
| Age (years) | 73.1 ± 5.3 | 73.0 ± 5.4 |
| Race | ||
| White | 3054 (78.8%) | 3055 (79.1%) |
| Black | 15 (0.4%) | 17 (0.4%) |
| Hispanic | 226 (5.8%) | 215 (5.6%) |
| Japanese | 9 (0.2%) | 12 (0.3%) |
| Other Asian | 553 (14.3%) | 547 (14.2%) |
| Other | 18 (0.5%) | 15 (0.4%) |
| Height(cm) | 154 ± 7.1 | 154 ± 7.1 |
| Weight (kg) | 59.9 ± 11.1 | 60.6 ± 11.3 |
| BMI (kg/m2) | 25.1 ± 4.3 | 25.4 ± 4.3 |
| Prevalent vertebral fractures | ||
| Yes, n (%) | 2416 (62.4%) | 2477 (64.2%) |
| Back pain (baseline) | ||
| Yes, n (%) | 2807 (72.9%) | 2783 (72.4%) |
| Of those, frequency of back pain | ||
| All or most of the time | 1190 (42.4%) | 1178 (42.4%) |
| Of those, severity of back pain | ||
| Very mild | 140 (5.0%) | 149 (5.4%) |
| Mild | 698 (24.9%) | 694 (24.9%) |
| Moderate | 1464 (52.2%) | 1447 (52.0%) |
| Severe/very severe | 505 (18.0%) | 493 (17.8%) |
| Number of days with back pain | ||
| n | 3863 | 3849 |
| Mean | 33.9 (36.4) | 33.5 (36.3) |